Medical-device maker Medtronic in talks to buy Irish rival

Jun 15, 2014

US medical-device maker Medtronic is in advanced talks to buy competitor Covidien, based in Ireland, for more than $40 billion, The Wall Street Journal reported Saturday.

The deal, which could be announced Monday, would allow Medtronic to take advantage of Ireland's lower business tax rates—12.5 percent versus 35 percent in the United States—in a process known as "tax inversion," the newspaper reported, citing people familiar with the matter.

According to the paper, the talks are well under way, but could still hit snags at the last minute.

A number of US companies, in particular in the , have recently launched bids to buy companies as a way to reduce their costs and tax burden and use their cash overseas.

Pfizer recently abandoned an attempt to buy British firm AstraZeneca for $117 billion in a deal that would have allowed the US company to take advantage of Britain's lower corporate tax rate.

The United States is considering amending its legislation to allow multinational companies to keep overseas indefinitely a portion of their profits in order to avoid paying US taxes on it.

Based in the midwestern US city of Minneapolis, Medtronic makes orthopedic and cardiovascular devices and is valued at around $61 billion, compared to Covidien's $32 billion. Covidien develops devices used in surgery, the Journal said.

Explore further: Google eyeing up to $30 billion in foreign buyouts

add to favorites email to friend print save as pdf

Related Stories

AstraZeneca fends off Pfizer with new growth plan

May 06, 2014

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival ...

Recommended for you

India's Flipkart raises $1 bn to tackle Amazon

1 hour ago

India's top e-commerce company Flipkart said Tuesday it had raised $1 billion (60 billion rupees) in funds as it battles US giant Amazon for supremacy in the hyper-competitive local market.

Pfizer's 2Q profit sinks 79 pct but tops forecasts

4 hours ago

(AP)—Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion. The latest results still edged ...

Aetna 2Q profit rises 2.4 percent

4 hours ago

Aetna's second-quarter profit climbed more than 2 percent, as gains from an acquisition helped the health insurer beat analyst expectations and raise its 2014 earnings forecast again.

Merck 2Q profit more than doubles

4 hours ago

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

BSD
not rated yet Jun 15, 2014
Finance, not science.
ryggesogn2
5 / 5 (1) Jun 16, 2014
Finance, not science.


That's why this story is in the Technology/Business section.